C. Light Technologies

C. Light Technologies has developed and commercialized an FDA-cleared non-invasive retinal eye-tracking device called Retitrack™, which uses advanced AI to analyze fixational eye movements as digital biomarkers of neurological health. The technology enables rapid (<10 seconds), objective assessment of brain and ocular conditions by quantifying micro-eye motions invisible to traditional pupil trackers. Their approach supports early detection, monitoring progression, and evaluating therapeutic efficacy in diseases such as multiple sclerosis, Alzheimer’s/mild cognitive impairment, Parkinson's disease, ALS, concussion/TBI, and certain retinal disorders.